Form 4 for CDT CDT Equity Inc.
Accepted 2025-12-22 00:00:00 ET · period of report 2025-12-08 · accession 0001493152-25-028761 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-12-22 | 2025-12-08 | CDT | Corvus Capital Ltd. | 10% | A - Grant | $1.79 | +224.8K | 227.3K | +8,978% | +$402.4K |
| DI | 2025-12-22 | 2025-12-08 | CDT | Corvus Capital Ltd. | 10% | A - Grant | $0.00 | +3.69M | 3.69M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-08 | A | A | 224,800 | $1.79 | 227,304 | I By Corvus Capital Ltd. | — | — | (F1) On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities. (F2) Based on the closing price per share of Common Stock on December 7, 2025. (F6) Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein. (F3) These shares of Common Stock are owned of record by Corvus. |
| 2 | Derivative | Pre-Funded Warrants | 2025-12-08 | A | A | 3,685,815 | $0.00 | 3,685,815 | I By Corvus Capital Ltd. | $0.00 · 2025-12-08 to — | 3,685,815 Common Stock | (F1) On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities. (F6) Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein. (F3) These shares of Common Stock are owned of record by Corvus. (F7) Until exercised in full. |